Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 9/2016

Open Access 01-08-2016 | Guidelines

The EANM practice guidelines for bone scintigraphy

Authors: T. Van den Wyngaert, K. Strobel, W. U. Kampen, T. Kuwert, W. van der Bruggen, H. K. Mohan, G. Gnanasegaran, R. Delgado-Bolton, W. A. Weber, M. Beheshti, W. Langsteger, F. Giammarile, F. M. Mottaghy, F. Paycha, On behalf of the EANM Bone & Joint Committee and the Oncology Committee.

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2016

Login to get access

Abstract

Purpose

The radionuclide bone scan is the cornerstone of skeletal nuclear medicine imaging. Bone scintigraphy is a highly sensitive diagnostic nuclear medicine imaging technique that uses a radiotracer to evaluate the distribution of active bone formation in the skeleton related to malignant and benign disease, as well as physiological processes.

Methods

The European Association of Nuclear Medicine (EANM) has written and approved these guidelines to promote the use of nuclear medicine procedures of high quality.

Conclusion

The present guidelines offer assistance to nuclear medicine practitioners in optimizing the diagnostic procedure and interpreting bone scintigraphy. These guidelines describe the protocols that are currently accepted and used routinely, but do not include all existing procedures. They should therefore not be taken as exclusive of other nuclear medicine modalities that can be used to obtain comparable results. It is important to remember that the resources and facilities available for patient care may vary.
Literature
1.
Kosuda S, Kaji T, Yokoyama H, Yokokawa T, Katayama M, Iriye T, et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? J Nucl Med. 1996;37:975–8.PubMed
2.
Horger M, Eschmann SM, Pfannenberg C, Vonthein R, Besenfelder H, Claussen CD, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR Am J Roentgenol. 2004;183:655–61.CrossRefPubMed
3.
Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, et al. Bone scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:BP99–BP106.PubMed
4.
5.
Commissie Kwaliteitsbevordering Nederlandse Vereniging Nucleaire Geneeskunde. Skeletscintigrafie. In: Barneveld P, van Urk P, editors. Aanbevelingen Nucleaire Geneeskunde. Neer: Kloosterhof acquisitie services – uitgeverij; 2007. p. 155–60.
6.
Société Française de Médecine Nucléaire et Imagerie Moléculaire (SFMN). Guidelines for writing protocols for bone scintigraphy. Med Nucl. 2012;687–97.
7.
Beheshti M, Mottaghy FM, Paycha F, Behrendt FF, Van den Wyngaert T, Fogelman I, et al. (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging. 2015;42:1767–77.CrossRefPubMed
8.
Segall G, Delbeke D, Stabin MG, Even-Sapir E, Fair J, Sajdak R, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51:1813–20.CrossRefPubMed
9.
Stauss J, Hahn K, Mann M, De Palma D. Guidelines for paediatric bone scanning with 99mTc-labelled radiopharmaceuticals and 18F-fluoride. Eur J Nucl Med Mol Imaging. 2010;37:1621–8.CrossRefPubMed
10.
Fogelman I, Gnanasegaran G, Van der Wall H. Radionuclide and hybrid bone imaging. Berlin: Springer; 2013.
11.
Yang DC, Ratani RS, Mittal PK, Chua RS, Pate SM. Radionuclide three-phase whole-body bone imaging. Clin Nucl Med. 2002;27:419–26.CrossRefPubMed
12.
Bares R. Skeletal scintigraphy in breast cancer management. Q J Nucl Med. 1998;42:43–8.PubMed
13.
Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med. 1999;29:69–79.CrossRefPubMed
14.
Cook GJ, Fogelman I. The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med. 2001;31:206–11.CrossRefPubMed
15.
Dose J, Bleckmann C, Bachmann S, Bohuslavizki KH, Berger J, Jenicke L, et al. Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic procedures” for the detection of distant metastases in breast cancer patients. Nucl Med Commun. 2002;23:857–64.CrossRefPubMed
16.
Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003;38:250–6.PubMed
17.
Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356–67.PubMed
18.
Orzel JA, Sawaf NW, Richardson ML. Lymphoma of the skeleton: scintigraphic evaluation. AJR Am J Roentgenol. 1988;150:1095–9.CrossRefPubMed
19.
Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med. 2000;27:1305–11.CrossRefPubMed
20.
Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375–9.PubMed
21.
Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun. 2001;22:875–9.CrossRefPubMed
22.
Hetzel M, Arslandemir C, Konig HH, Buck AK, Nussle K, Glatting G. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18:2206–14.CrossRefPubMed
23.
Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med. 2003;28:302–7.PubMed
24.
Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol. 2005;184:1266–73.CrossRefPubMed
25.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.CrossRefPubMedPubMedCentral
26.
Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30:519–24.CrossRefPubMedPubMedCentral
27.
Duer A, Ostergaard M, Horslev-Petersen K, Vallo J. Magnetic resonance imaging and bone scintigraphy in the differential diagnosis of unclassified arthritis. Ann Rheum Dis. 2008;67:48–51.CrossRefPubMed
28.
Ryan PJ, Gibson T, Fogelman I. Spinal bone SPECT in chronic symptomatic ankylosing spondylitis. Clin Nucl Med. 1997;22:821–4.CrossRefPubMed
29.
Guglielmi G, Cascavilla A, Scalzo G, Salaffi F, Grassi W. Imaging of sternocostoclavicular joint in spondyloarthropathies and other rheumatic conditions. Clin Exp Rheumatol. 2009;27:402–8.PubMed
30.
Makki D, Khazim R, Zaidan AA, Ravi K, Toma T. Single photon emission computerized tomography (SPECT) scan-positive facet joints and other spinal structures in a hospital-wide population with spinal pain. Spine J. 2010;10:58–62.CrossRefPubMed
31.
Dieppe P, Cushnaghan J, Young P, Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis. 1993;52:557–63.CrossRefPubMedPubMedCentral
32.
Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB. Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw. Clin Nucl Med. 2011;36:17–20.CrossRefPubMed
33.
Brown ML, Collier Jr BD, Fogelman I. Bone scintigraphy: Part 1. Oncology and infection. J Nucl Med. 1993;34:2236–40.PubMed
34.
Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647–58.CrossRefPubMed
35.
Jutte P, Lazzeri E, Sconfienza LM, Cassar-Pullicino V, Trampuz A, Petrosillo N, et al. Diagnostic flowcharts in osteomyelitis, spondylodiscitis and prosthetic joint infection. Q J Nucl Med Mol Imaging. 2014;58:2–19.PubMed
36.
Collier Jr BD, Fogelman I, Brown ML. Bone scintigraphy: Part 2. Orthopedic bone scanning. J Nucl Med. 1993;34:2241–6.PubMed
37.
Holder LE. Bone scintigraphy in skeletal trauma. Radiol Clin North Am. 1993;31:739–81.PubMed
38.
Di Leo C, Tarolo GL, Aliberti G, Ardemagni A, Conte A, Bestetti A, et al. Stress fracture and coexistent periosteal reaction (“shin splints”) in a young athlete revealed by bone scintigraphy. Nuklearmedizin. 2000;39:N50–1.PubMed
39.
Huellner MW, Burkert A, Strobel K, Perez Lago Mdel S, Werner L, Hug U, et al. Imaging non-specific wrist pain: interobserver agreement and diagnostic accuracy of SPECT/CT, MRI, CT, bone scan and plain radiographs. PLoS One. 2013;8:e85359.CrossRefPubMedPubMedCentral
40.
Fogelman I, Collier BD, Brown ML. Bone scintigraphy: Part 3. Bone scanning in metabolic bone disease. J Nucl Med. 1993;34:2247–52.PubMed
41.
Mari C, Catafau A, Carrio I. Bone scintigraphy and metabolic disorders. Q J Nucl Med. 1999;43:259–67.PubMed
42.
Hain SF, Fogelman I. Nuclear medicine studies in metabolic bone disease. Semin Musculoskelet Radiol. 2002;6:323–9.CrossRefPubMed
43.
44.
de Graaf P, Schicht IM, Pauwels EK, te Velde J, de Graeff J. Bone scintigraphy in renal osteodystrophy. J Nucl Med. 1978;19:1289–96.PubMed
45.
de Jonge FA, Pauwels EK, Hamdy NA. Scintigraphy in the clinical evaluation of disorders of mineral and skeletal metabolism in renal failure. Eur J Nucl Med. 1991;18:839–55.CrossRefPubMed
46.
ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP. 2008;38:1–197.CrossRefPubMed
47.
Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, et al. Cabozantinib resolves bone scans in tumor-naive mice harboring skeletal injuries. Mol Imaging. 2014;13:7290.2014.00026. doi:10.​2310/​7290.​2014.​00026.
48.
Lassmann M, Treves ST. Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging. 2014;41:1036–41.CrossRefPubMed
49.
50.
Busemann Sokole E, Plachcinska A, Britten A, Lyra Georgosopoulou M, Tindale W, Klett R. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging. 2010;37:662–71.CrossRefPubMed
51.
Brown ML, O’Connor MK, Hung JC, Hayostek RJ. Technical aspects of bone scintigraphy. Radiol Clin North Am. 1993;31:721–30.PubMed
52.
Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800–4.PubMed
53.
Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for SPECT/CT imaging 1.0. J Nucl Med. 2006;47:1227–34.PubMed
54.
Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Turler A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41:59–67.CrossRefPubMed
55.
Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17:4854–61.CrossRefPubMedPubMedCentral
56.
ICRP. Radiation dose to patients from radiopharmaceuticals (addendum to ICRP publication 53). ICRP publication 80. Ann ICRP. 1998;28:1–126.
57.
Mettler Jr FA, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology. 2008;248:254–63.CrossRefPubMed
58.
Brix G, Nekolla EA, Borowski M, Nosske D. Radiation risk and protection of patients in clinical SPECT/CT. Eur J Nucl Med Mol Imaging. 2014;41 Suppl 1:S125–36.CrossRefPubMed
Metadata
Title
The EANM practice guidelines for bone scintigraphy
Authors
T. Van den Wyngaert
K. Strobel
W. U. Kampen
T. Kuwert
W. van der Bruggen
H. K. Mohan
G. Gnanasegaran
R. Delgado-Bolton
W. A. Weber
M. Beheshti
W. Langsteger
F. Giammarile
F. M. Mottaghy
F. Paycha
On behalf of the EANM Bone & Joint Committee and the Oncology Committee.
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3415-4

Other articles of this Issue 9/2016

European Journal of Nuclear Medicine and Molecular Imaging 9/2016 Go to the issue

Original Article

Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease

Original Article

Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers

Original Article

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study

Original Article

In vivo PET imaging of the neuroinflammatory response in rat spinal cord injury using the TSPO tracer [18F]GE-180 and effect of docosahexaenoic acid

Original Article

18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial

Original Article

Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing